

## CURRICULUM VITAE

### PERSONAL DATA

*Name* **Beverly Shriver Mitchell, M.D.**

### EDUCATION

*Undergraduate* Smith College, Northampton, Massachusetts  
1961-1965, A.B. in Biochemistry, Summa cum laude

*Graduate/Professional* Harvard Medical School, Boston, Massachusetts  
1965-1969, M.D. in Medicine

### POSTDOCTORAL TRAINING

*Internship* Harborview Medical Center, Seattle, Washington, 1969-1970

*Residency* Junior, Senior Resident, Internal Medicine  
University of Washington, Seattle, Washington, 1970-1972  
Chief Medical Resident and Instructor in Medicine  
Veterans Administration Hospital, University of  
Washington Seattle, Washington, 1972-1973

*Fellowship* Research Fellow, Metabolic Laboratory, Kinderspital  
University of Zurich, Zurich, Switzerland, 1973-1975  
Hematology Fellow, Division of Hematology and  
Oncology, University of Michigan, Ann Arbor, Michigan,  
1975-1977

### ACADEMIC APPOINTMENTS

#### **University of Michigan, Ann Arbor, Michigan**

Instructor, Internal Medicine, Division of Hematology and Oncology, 1977-1978

Assistant Professor, Internal Medicine, Division of Hematology and Oncology, 1978-1981

Associate Professor, Internal Medicine, Division of Hematology and Oncology, 1981-1987

Visiting Scientist, Fred Hutchinson Cancer Research Center, Seattle, Washington, 1984

Professor, Internal Medicine, Division of Hematology Oncology, 1987-1991

Professor of Pharmacology, 1987-1991

## **ACADEMIC APPOINTMENTS CONTINUED**

### **University of North Carolina, Chapel Hill, North Carolina**

Professor of Internal Medicine and Pharmacology, 1991-2005  
Wellcome Distinguished Professor of Cancer Research, 1991-2005  
Head, Molecular Therapeutics Program; Member, Curriculum in Genetics,  
Lineberger Comprehensive Cancer Center, 1991-2005  
Chief, Division of Hematology/Oncology, 1994-2003  
Associate Director, Lineberger Comprehensive Cancer Center 1994-2005

### **Stanford University, Stanford, California**

George E. Becker Professor of Medicine, 2005-present  
Deputy Director, Stanford Cancer Center, 2005-2008  
Director, Stanford Cancer Center, 2008-present

## **SCIENTIFIC ACTIVITIES**

### **Study Sections**

Biochemical Pharmacology: Ad Hoc Study Section, Mar 1986  
Biochemistry 2: Ad Hoc, 1986  
NCI site visits: 1989 (2); 1993 (chair); 1996; 1997  
Biochemistry 2: Permanent Member October 1997 - Jun 1991  
NCI special study section for Outstanding Investigator Awards: Jan 1992; Nov 1993  
NHLBI Loan Forgiveness Program: 2002; 2003  
Leukemia Lymphoma Society of America: Translational Grants, 1999-present;  
Translational Grants Chair, 2003; 2004  
SCOR reviews 2011  
NCI Cancer Center site visits and SPORC reviews: 2008, 2009, 2010, 2011  
NCI CCSG Parent Committee 2011-present

### **Editorial Boards**

Journal of Laboratory and Clinical Medicine: 1987-1993  
American Journal of Hematology: Associate Editor, 1990-present  
American Journal of the Medical Sciences: 1992-1998  
Journal of Clinical Investigation-Editorial Committee: 1992-1997  
Clinical Investigator: 1993-1995  
Blood: 2002-2007  
Blood Cells, Molecules and Diseases: 2002-present

### **Advisory Boards**

National Cancer Institute, Division of Cancer Treatment:  
Board of Scientific Counselors, 1993-1995  
NIDDK: Ad hoc advisory committee, 1993  
National Cancer Institute: Board of Scientific Counselors 1998-2003

Burroughs Wellcome Fund Advisory Committee, 1995-1998  
AAMC Research Advisory Council, 1999-2002  
Leukemia and Lymphoma Society of America: Chair, Medical and Scientific Affairs  
Committee, 2003-2006;  
Vice-Chair for Medical and  
Scientific Affairs 2004-2006  
Burroughs Wellcome Fund: Translational Grant Award Committee 2002-2006;  
Co-chair 2005  
Knight Cancer Center, Oregon Health Sciences University 2008-present  
James Cancer Center, Ohio State University 2008-present  
Brown Cancer Center, University of Louisville 2011  
Duke Comprehensive Cancer Center 2012-present (chair)  
City of Hope Comprehensive Cancer Center 2014-

### **Consulting Positions**

Burroughs Wellcome Company, 1991-1995  
Gensia Pharmaceuticals, 1992-1996  
Vertex Pharmaceuticals, 1995-1998, 2003  
Salmedix Pharmaceuticals, 2003  
Avalon Pharmaceuticals, 2006-2009

### **CERTIFICATION AND LICENSURE**

American Board of Internal Medicine, Internal Medicine, Certified, 1973  
American Board of Internal Medicine, Hematology, Certified, 1978  
Washington Medical License, 1970-1973  
Michigan Medical License 1975-1992  
North Carolina Medical License 1992-present  
California Medical License 2006-present

### **HONORS AND AWARDS**

A.B. Summa cum laude; Phi Beta Kappa; Sigma Xi, 1965  
NIH Clinical Investigator Award, 1978-1981  
Jerome W. Conn Award for Excellence in Research, Department of Medicine,  
University of Michigan, 1979  
Scholar Award of the Leukemia Society of America, 1982-1987  
H. Marvin Pollard Award for Outstanding Resident Teaching, 1983  
Stohlman Award, Leukemia Society of America, 1988  
American Society for Clinical Investigation, 1989  
Association of American Physicians, 1991  
National Academy of Sciences, Institute of Medicine, Induction 2001

Smith College Medal – Distinguished Alumna, 2006  
Albion Walter Hewlett Award, Stanford University 2011  
American Society of Hematology Mentoring Award 2012  
Fellows of the American Association for the Advancement of Science 2015

### **MEMBERSHIPS AND OFFICES IN PROFESSIONAL SOCIETIES**

American Society of Clinical Oncology  
American Society for Clinical Investigation  
American Association for Cancer Research  
American Society of Hematology: Treasurer 1991-1996 Financial Affairs Committee 1997-1999; Nominating Committee 1997; Vice President 1999; President Elect 2000; President 2001; Co-leader-ASH Clinical Research Training Institute 2003-2005; Chair of Awards Committee 2004-7; Nominating Committee, 2008-2011; Chair 2009-2011  
Burroughs Wellcome Fund Translational Award Committee and Co-Chair 2002-2009  
Leukemia and Lymphoma Society of America: Vice Chair 2003-2006  
American Association of Cancer Institutes 2006-present; Council 2010-2014  
Institute of Medicine Membership Committee 2009-2011  
Association of American Physicians; AAP Council 2010-2015

### **ACTIVE GRANT SUPPORT**

2P30CA124435-09 (Mitchell) 06/04/07-05/31/21  
National Cancer Institute  
*Stanford University Cancer Institute*

The major goal of this project is to build on institutional strengths in both technology development and translational research to foster interdisciplinary collaborations directed at the detection, prevention and treatment of cancer patients. Research programs include Cancer Biology, Radiation Biology, Cancer Stem Cells, Cancer Imaging Research, Translational Oncology, Lymphoma and Leukemia, Immunotherapy of Cancer, and Population Sciences. Shared resources subsidized by this grant support the investigations in experimental and clinical research.

### **PENDING GRANT SUPPORT**

CLIN1-09214  
California Institute for Regenerative Medicine  
Development of Sudemycin 6 in Patients with Myelodysplastic Syndrome  
B. Mitchell, PI

## **CLINICAL AND TEACHING ACTIVITIES**

### **University of Michigan**

Lecturer, Introduction to Clinical Science, M1 and M2 classes, 1980-1991  
Lecturer, Pharmacology 500, 1988-1991  
Lecturer, Medical Pharmacology, 1990 - 1991  
Lecturer, Experimental Therapeutics 1986-1991  
Short Course Director, Mechanisms of Resistance to Chemotherapeutic Agents,  
Department of Pharmacology, 1988  
Rounding, three months/year on Hematology Inpatient, Consults and Internal Medicine

### **The University of North Carolina at Chapel Hill**

Course Director, Hematology/Oncology, Second Year Medical Students, 1993-1994;  
Associate Director, Hematology/Oncology, Second Year Medical Students, 1994-  
2004  
Rounding, two months/year on Hematology/Oncology inpatient service  
Co-Director, Genomic Instability and Cancer Progression, Lineberger Cancer Center, 2005

### **Stanford University**

Rounding, Hematology Consults, 1 month/year  
Hematology Clinic, ½ day/week

## **ADMINISTRATIVE ACTIVITIES**

### **University of Michigan**

Acting Division Chief, Hematology/Oncology, 1983-1984  
Cancer Research Committee, 1985-1991  
Medical Scientist Training Program Executive Board, 1987-1991  
Department of Medicine Promotions Committee, 1987-1990; Chairman 1989-1990  
Medical School Appointment and Promotions Committee, 1989-1991  
Trustee, Michigan Chapter, Leukemia Society of America, 1988-1991  
Associate Division Chief for Hematology, 1989-1990  
Search Committee, Pharmacology Chairman, 1989-1990

### **The University of North Carolina at Chapel Hill**

Head, Molecular Therapeutics Program, Lineberger Comprehensive Cancer Center  
Associate Director, Lineberger Comprehensive Cancer Center, 1991-2005  
Chief, Division of Hematology/Oncology 1994-2003  
Search Committees: Chief of Cardiology, 1992; Hematopathology 2000, 2003  
Advisory Committee, Clinical Research Center, 1992-1995  
Gene Therapy Advisory Committee, 1992  
Howard Hughes Advisory Committee, 1993

Search Committee, Vice Chancellor for Graduate Studies and Research, 1993  
Dean's Research Advisory Council, 1998-2001  
Department of Medicine Research Advisory Committee, 2001-2005  
Director, Junior Faculty Development, Department of Medicine, 2003-2005

### **Stanford University School of Medicine**

Search Committee, Department of Medicine Chair 2006  
Executive Committee, School of Medicine 2006-present  
Search Committee Chair, Medical Director of Stanford Cancer Center  
Search Committee Chair, Chair of Radiation Oncology 2010-2011  
Leadership Academy, Stanford University, 2010-2011

### **BIBLIOGRAPHY**

#### **Peer Reviewed Articles:**

- Bamford S, Cassin C, and **Mitchell B**. Sex chromatin determinations in selected cases of developmental sex abnormalities. *Acta Cytol* 1963; 7:151-158. PMID: 13966268
- Mitchell B**, and Szabo G. The effect of phenylthiourea on melanogenesis of *Fundulus Heteroclitus*. *Biological Bulletin* 1966; 131:398-399. PMID: unavailable
- Modan B, Goldman B, Shani M, Meytes D, and **Mitchell BS**. Epidemiological aspects of neoplastic disorders in Israeli migrant populations. V. The lymphomas. *J Nat Cancer Inst* 1969; 42:375-381. PMID: 4887880
- Mitchell B**, Haigis E, Steinmann B, and Gitzelmann R. Reversal of UDP-galactose 4-epimerase deficiency of human leukocytes in culture. *Proc Nat Acad Sci (USA)* 1975; 72:5026-5030. PMID: 388868
- Gitzelmann R, Steinmann B, **Mitchell B**, and Haigis E. Uridine diphosphate galactose 4'-epimerase deficiency. IV. Report of eight cases in three families. *Helv Paediatr Acta* 1977; Apr;31(6):441-452. PMID: 404274
- Mitchell BS, Mejias E, Daddona PE, and Kelley WN. Purinogenic immunodeficiency diseases: selective toxicity of deoxyribonucleosides for T-cells. *Proc Natl Acad Sci (USA)* 1978; Oct;75(10):5011-5014. PMID: 311004
- Wortmann RL, **Mitchell BS**, Edwards NL, and Fox IH. Biochemical basis for differential deoxyadenosine toxicity to T and B lymphoblasts: role for 5'-nucleotidase. *Proc Natl Acad Sci (USA)* 1979; May;76(5):2434-2437. PMID: 221924
- Wilson J, **Mitchell B**, Daddona P, and Kelley W. Purinogenic immunodeficiency diseases: Differential effects of deoxyadenosine and deoxyguanosine on DNA synthesis in human T-lymphoblasts. *J Clin Invest* 1979 Nov;64(5):1475-1484. PMID: 115901
- Koller CA, **Mitchell BS**, Grever MR, Mejias E, Malspeis L, and Metz EN. Treatment of acute lymphoblastic leukemia with 2'-deoxycoformycin: clinical and biochemical consequences of adenosine deaminase inhibition. *Cancer Treat Rep* 1979 Nov-Dec;63(11-12):1949-1952. PMID: 316725
- Mitchell BS**, and Kelley WN. Purinogenic immunodeficiency disease: clinical features and molecular mechanisms. *Ann Intern Med* 1980 Jun;92(6):826-831. PMID: 6247948

- Mitchell BS**, Koller CA, and Heyn R. Inhibition of adenosine deaminase activity results in cytotoxicity to T lymphoblasts in vivo. *Blood* 1980 Sep;56(3):556-559. PMID: 6967747
- Koller CA, Stetson PL, Nichamin LD, and **Mitchell BS**. An assay of deoxyadenosine and adenosine in human plasma by HPLC. *Biochem Med* 1980 Oct;24(2):179-184. PMID: 6970035
- Siaw MF, **Mitchell BS**, Koller CA, Coleman MS, and Hutton JJ. ATP depletion as a consequence of adenosine deaminase inhibition in man. *Proc Natl Acad Sci USA* 1980 Oct; 77(10):6157-6161. PMID: 6969403
- Kazmers IS, **Mitchell BS**, Daddona PE, Wotring LL, Townsend LB, and Kelley WN. Inhibition of purine nucleoside phosphorylase by 8-aminoguanosine: selective toxicity for T lymphoblasts. *Science* 1981 Dec 4; 214(4525):1137-1139. PMID: 6795718
- Koller CA, and **Mitchell BS**. Alterations in erythrocyte adenine nucleotide pools resulting from 2'-deoxycoformycin therapy. *Cancer Res* 1983 Mar;43(3):1409-1414. PMID: 6600652
- Daddona PE, **Mitchell BS**, Meuwissen HJ, Davidson BL, Wilson JM, and Koller CA. Adenosine deaminase deficiency with normal immune function. An acidic enzyme mutation. *J Clin Invest* 1983 Aug;72(2):483-492. PMID: 6603477
- Mitchell BS**, Edwards NL, and Koller CA. Deoxyribonucleoside triphosphate accumulation by leukemic cells. *Blood* 1983 Aug;62(2):419-424. PMID: 6603241
- Hershfield MS, Kredich NM, Koller CA, **Mitchell BS**, Kurtzberg J, Kinney TR, and Falletta JM. S-adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2'-deoxycoformycin alone and in combination with 9-beta-D-arabinofuranosyladenine. *Cancer Res* 1983 Jul;43(7):3451-3458. PMID: 6601986
- Mitchell BS**, and Edwards NL. Purine metabolizing enzymes as predictors of lymphoblast sensitivity to deoxyadenosine. *J Lab Clin Med* 1984 Sep;104(3):414-424. PMID: 6147383
- Sidi Y, and **Mitchell BS**. 2'-deoxyguanosine toxicity for B and mature T lymphoid cell lines is mediated by guanine ribonucleotide accumulation. *J Clin Invest* 1984 Nov;74(5):1640-1648. PMID: 6334099
- Sidi Y, Edwards NL, Winkler C, Bunn P, and **Mitchell BS**. Differential metabolism of deoxyribonucleosides by leukaemic T cells of immature and mature phenotype. *Br J Haematol* 1985 Sep;61(1):125-134. PMID: 2996581
- Mitchell BS**, and Sidi Y. Differential metabolism of guanine nucleosides by human lymphoid cell lines. *Proc Soc Exp Biol Med* 1985 Sep;179(4):427-431. PMID: 3875100
- Shewach DS, Daddona PE, Ashcraft E, and **Mitchell BS**. Metabolism and selective cytotoxicity of 9-beta-D-arabinofuranosylguanine in human lymphoblasts. *Cancer Res* 1985 Mar;45(3):1008-1014. PMID: 3971358
- Sidi Y, Hudson JL, and **Mitchell BS**. Effects of guanine ribonucleotide accumulation on the metabolism and cell cycle of human lymphoid cells. *Cancer Res* 1985 (Oct);45(10):4940-4945. PMID: 2411392

- Sidi Y, and **Mitchell BS**. Z-nucleotide accumulation in erythrocytes from Lesch-Nyhan patients. *J Clin Invest* 1985 Dec;76(6):2416-2419. PMID: 4077987
- Chottiner EG, Cloft HJ, Tartaglia AP, and **Mitchell BS**. Elevated adenosine deaminase activity and hereditary hemolytic anemia. Evidence for abnormal translational control of protein synthesis. *J Clin Invest* 1987 Mar;79(3):1001-1005. PMID: 3029177
- Simpson RU, Hsu T, Begley DA, **Mitchell BS**, and Alizadeh BN. Transcriptional regulation of the c-myc protooncogene by 1,25-dihydroxyvitamin D3 in HL-60 promyelocytic leukemia cells. *J Biol Chem* 1987 Mar 25;262(9):4104-4108. PMID: 2435730
- Gan TE, Daddona PE, and **Mitchell BS**. Genetic expression of adenosine deaminase in human lymphoid malignancies. *Blood* 1987 May;69(5):1376-1380. PMID: 3567360
- Datta NS, Shewach DS, Hurley MC, **Mitchell BS**, and Fox IH. Human T-lymphoblast deoxycytidine kinase: purification and properties. *Biochemistry* 1989 JAN 10;28(1):114-123. PMID: 2539852
- Chottiner EG, Ginsburg D, Tartaglia AP, and **Mitchell BS**. Erythrocyte adenosine deaminase overproduction in hereditary hemolytic anemia. *Blood* 1989 Jul;74(1):448-453. PMID: 2752123
- Gribbin TE, Stein CK, Harrison JS, Glover TW, Hanson CA, Wasmuth JJ, Cody RL, and **Mitchell, BS**. Association of a mature B cell leukemia with a 4p+ chromosomal abnormality: derivation and characterization of a cell line. *Leukemia* 1989 Sep;3(9):643-647. PMID: 2548046
- Gribbin T, Chottiner E, Ginsburg D, and **Mitchell B**. Identification of an Apa I polymorphism within the human adenosine deaminase (ADA) gene. *Nucleic Acids Res* 1989 May 11;17(9):3626. PMID: 2566983
- Datta NS, Shewach DS, **Mitchell BS**, and Fox IH. Kinetic properties and inhibition of human T lymphoblast deoxycytidine kinase. *J Biol Chem* 1989 Jun5;264(16):9359-9364. PMID: 2542307
- Shewach DS, and **Mitchell BS**. Differential metabolism of 9-beta-D-arabinofuranosylguanine in human leukemic cells. *Cancer Res*, 1989 Dec 1;49(23):6498-6502. PMID: 2819707
- Hanson CA, Gribbin TE, Schnitzer B, Schlegelmilch JA, and **Mitchell BS**, Stoolman LM. CD11c (LEU-M5) expression characterizes a B-cell chronic lymphoproliferative disorder with features of both chronic lymphocytic leukemia and hairy cell leukemia. *Blood* 1990 Dec 1;76(11):2360-2367. PMID: 1701669
- Mattano SS, Palella TD, and **Mitchell BS**. Mutations induced at the hypoxanthine-guanine phosphoribosyltransferase locus of human T-lymphoblasts by perturbations in purine deoxynucleoside triphosphate pools. *Cancer Res* 1990 Aug 1;50(15):4566-4571. PMID: 2369732
- Turka LA, Dayton J, Sinclare G, Thompson CB, and **Mitchell BS**. Guanine ribonucleotide depletion inhibits T cell activation. Mechanism of action of the



immunosuppressive drug mizoribine. *J Clin Invest* 1991 Mar;87(3):940-948. PMID: 1999502

Chottiner EG, Shewach DS, Datta NS, Ashcraft E, Gribbin D, Ginsburg D, Fox IH, **Mitchell BS**. Cloning and expression of human deoxycytidine kinase cDNA. *Proc Natl Acad Sci USA* 1991 Feb 15;88(4):1531-1535. PMID: 1996353

Dayton JS, Turka LA, Thompson CB, **Mitchell BS**. Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine, and mycophenolic acid on T lymphocyte proliferation and purine ribonucleotide metabolism. *Mol Pharmacol* 1992 Apr;41(4):671-676. PMID: 1569921

Owens JK, Shewach DS, Ullman B, **Mitchell BS**. Resistance to 1-beta-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene. *Cancer Res* 1992 May 1;52(9):2389-2393. PMID: 1568208

Song JJ, Walker S, Chen E, Johnson EE 2nd, Spychala J, Gribbin T and **Mitchell, BS**. Genomic structure and chromosomal localization of the human deoxycytidine kinase gene. *Proc Natl Acad Sci USA*, 1993 Jan 15;90(2):431-434. PMID: 8421671

Dayton JS, Lindsten T, Thompson CB, and **Mitchell BS**. Effects of human T lymphocyte activation on inosine monophosphate dehydrogenase expression. *J Immunol*, 1994 Feb 1; 152(3):984-991. PMID: 7905505

Chen EH, Tartaglia AP, and **Mitchell BS**. Hereditary overexpression of adenosine deaminase in erythrocytes: evidence for a cis-acting mutation. *Am J Hum Genet*, 1993 Oct;53(4):889-893. PMID: 8213817

Dayton JS and **Mitchell BS**. Type I inosine monophosphate dehydrogenase: evidence for a single functional gene in mammalian species. *Biochem Biophys Res Commun*, 1993 Sep 15;195(2):897-901. PMID: 7690562

Chen EH and **Mitchell BS**. Hereditary overexpression of adenosine deaminase in erythrocytes: studies in erythroid cell lines and transgenic mice. *Blood*, 1994 Oct 1;84(7):2346-2353. PMID: 7919352

Flasshove M, Strumberg D, Ayscue L, **Mitchell BS**, Tirier C, Heit W, Seeber S and Schutte J. Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside. *Leukemia*, 1994 May;8(5):780-785. PMID: 7514246

Gu JJ, Kaiser-Rogers K, Rao K, and **Mitchell BS**. Assignment of the human type 1 IMP dehydrogenase gene (IMPDH1) to chromosome 7q31.3-q32. *Genomics*, 1994 Nov 1;24(1):179-181. PMID: 7896275

Chen EH, Johnson EE 2<sup>nd</sup>, Vetter SM, and **Mitchell BS**. Characterization of the deoxycytidine kinase promoter in human lymphoblast cell lines. *J Clin Invest*, 1995 Apr;95(4):1660-1668. PMID: 7706474

Catapano CV, Dayton JS, **Mitchell BS**, and Fernandes DJ. GTP depletion induced by IMP dehydrogenase inhibitors blocks RNA-primed DNA synthesis. *Mol Pharmacol*, 1995 May;47(5):948-955. PMID: 7746281

Hager PW, Collart FR, Huberman E, and **Mitchell BS**. Recombinant human inosine monophosphate dehydrogenase type I and type II proteins. Purification and

characterization of inhibitor binding. *Biochem Pharmacol.* 1995 May 11;49(9):1323-1329. PMID: 7763314

Zimmermann AG, Spsychala J and **Mitchell, BS**. Characterization of the human inosine-5'-monophosphate dehydrogenase type II gene. *J Biol Chem*, 1995 Mar 24;270(12):6808-6814. PMID: 7896827

Spsychala J, Datta NS, Takabayashi K, Datta M, Fox IH, Gribbin T, and **Mitchell BS**. Cloning of human adenosine kinase cDNA: sequence similarity to microbial ribokinases and fructokinases. *Proc Natl Acad Sci USA* 1996 Feb 6;93(3):1232-1237. PMID: 8577746

Hapke DM, Stegmann AP, and **Mitchell BS**. Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity. *Cancer Res*, 1996 MAY15;56(10):2343-2347. PMID: 8625309

Manome Y, Wen PY, Dong Y, Tanaka T, **Mitchell BS**, Kufe DW and Fine, HA. Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. *Nat Med*, 1996May;2(5):567-573. PMID: 8616717

Kang SH, Sinhababu AK, Cory JG, **Mitchell B**, Thakker DR, and Cho MJ. Cellular delivery of nucleoside diphosphates: a prodrug approach. *Pharm Res*, 1997 Jun;14(6):706-712. PMID: 9210185

Spsychala J, **Mitchell BS**, Barankiewicz, J. Adenosine metabolism during phorbol myristate acetate-mediated induction of HL-60 cell differentiation: changes in expression pattern of adenosine kinase, adenosine deaminase, and 5'-nucleotidase. *J Immunol* 1997 May 15;158(10):4947-4952. PMID: 9144513

Zimmerman AG, Wright KL, Ting JP, **Mitchell BS**. Regulation of inosine-5'-monophosphate dehydrogenase type II gene expression in human T cells. Role for a novel 5' palindromic octamer sequence. *J Biol Chem* 1997 Sep 5;272(36):22913-22923. PMID: 9278455

Gu JJ, Spsychala J, and **Mitchell BS**. Regulation of the human inosine monophosphate dehydrogenase type I gene. Utilization of alternative promoters. *J Biol Chem*, 1997 Feb 14;272(7): 4458-4466. PMID: 9020170

Laliberté J, Yee A, Xiong Y, **Mitchell BS**. Effects of guanine nucleotide depletion on cell cycle progression in human T lymphocytes. *Blood*, 1998 Apr 15;91(8):2896-2904. PMID: 9531600

Gandhi V, Plunkett W, Rodriguez CO Jr, Nowak BJ, Du M, Ayres M, Kisor DF, **Mitchell BS**, Kurtzberg J, Keating MJ. Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. *J Clin Oncol*, 1998 Nov;16(11):3607-3615. PMID: 9817282

Spsychala J, Chen V, Oka J, **Mitchell BS**. ATP and phosphate reciprocally affect subunit association of human recombinant High Km 5'-nucleotidase. Role for the C-terminal polyglutamic acid tract in subunit association and catalytic activity. *Eur J Biochem*, 1999 Feb;259(3):851-858. PMID: 10092873

Gangi-Peterson L, Sorscher DH, Reynolds JW, Kepler TB, and **Mitchell BS**. Nucleotide pool imbalance and adenosine deaminase deficiency induce alterations of

N-region insertions during V(D)J recombination. *J Clin Invest*, 1999 Mar;103(6):833-841. PMID: 10079104

Spychala J, Zimmermann AG, **Mitchell BS**. Tissue-specific regulation of the ecto-5'-nucleotidase promoter. Role of the camp response element site in mediating repression by the upstream regulatory region. *J Biol Chem*, 1999 Aug 6;274(32):22705-12. PMID: 10428853

Mahajan KN, Gangi-Peterson L, Sorscher DH, Wang J, Gathy KN, Mahajan NP, Reeves WH, **Mitchell BS**. Association of terminal deoxynucleotidyl transferase with Ku. *Proc Natl Acad Sci USA*, 1999 Nov 23;96(24):13926-31. PMID: 10570175

Kisor DF, Plunkett W, Kurtzberg J, **Mitchell B**, Hodge JP, Ernst T, Keating MJ, Gandhi V. Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. *J Clin Oncol*. 2000 Mar;18(5):995-1003. PMID: 10694549

Gu JJ, Stegmann S, Gathy K, Murray R, Laliberte J, Ayscue L, **Mitchell BS**. Inhibition of T lymphocyte activation in mice heterozygous for loss of the IMPDH II gene. *J Clin Invest*. 2000 Aug;106(4):599-606. PMID: 10953035

Hunsucker SA, Spychala J, **Mitchell BS**. Human cytosolic 5'-nucleotidase I: characterization and role in nucleoside analog resistance. *J Biol Chem*. 2001 Mar 30;276(13):10498-10504. PMID: 11133996

Orlowski RZ, Stinchcombe TE, **Mitchell BS**, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine DL, Elliott PJ, Pien CS, Guerciolini R, Anderson JK, Depcik-Smith ND, Bhagat R, Lehman MJ, Novick SC, O'Connor OA, and Soignet SL. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. *J Clin Oncol*. 2002 Nov 15;20(22):4420-4427. PMID: 12431963

Rai KR, Freter CE, Mercier RJ, Cooper MR, **Mitchell BS**, Stadtmauer EA, Santabarbara P, Wacker B, Brettman L. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. *J Clin Oncol*. 2002 Sep 15;20(18):3891-3897. PMID: 12228210

Huang M, Wang Y, Collins M, Gu JJ, **Mitchell BS**, Graves LM. Inhibition of nucleoside transport by p38 MAPK inhibitors. *J Biol Chem*. 2002 Aug 9;277(32):28364-28367. PMID: 12077112

Huang M, Wang Y, Collins M, **Mitchell BS**, and Graves LM. A77 1726 induces differentiation of human myeloid leukemia K562 cells by depletion of intracellular CTP pools. *Mol. Pharmacol*, 2002 Sep;62(3):463-472. PMID: 12181422

Rodriguez CO, **Mitchell BS**, Ayres M, Eriksson E, and Gandhi V. Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. *Cancer Res*. 2002 Jun 1;62(11):3100-3105. PMID: 12036920

Mahajan KN, Nick McElhinny SA, **Mitchell BS**, Ramsden DA. Association of DNA polymerase Mu (pol mu) with Ku and ligase IV: role for pol mu in end-joining double-strand break repair. *Mol Cell Biol*, 2002 Jul;22(14):5194-5202. PMID: 12077346

Spychala J and **Mitchell BS**. Cyclosporin A and FK506 decrease adenosine kinase activity and adenosine uptake in T-lymphocytes. *J Lab Clin Med*. 2002 Aug;140(2):84-91. PMID: 12228764

- van Deventer HW, Hall MD, Orlowski RZ, **Mitchell BS**, Berkowitz LR, Hogan C, Dunphy CH, Koehler J, and Shea TC. Clinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous leukemia. *Am J Hematol*, 2002 Nov;71(3):184-190. PMID: 12410573
- Gu JJ, Gathy K, Santiago L, Chen E, Huang M, Graves LM, and **Mitchell BS**. Induction of apoptosis in IL-3 dependent hematopoietic cell lines by guanine nucleotide depletion. *Blood*, 2003 Jun 15;101(12): 4958-4965. PMID: 12609835
- Gu JJ, Tolin AK, Jain J, Huang H, Santiago L, **Mitchell BS**. Targeted disruption of inosine-5'-monophosphate dehydrogenase type I gene in mice. *Mol Cell Biol*, 2003 Sep;23(18):6702-6712. PMID: 12944494
- Huang M, Wang Y, Cogut SB, **Mitchell BS**, Graves LM. Inhibition of nucleoside transport by protein kinase inhibitors. *J Pharmacol Exp Ther* 2003 Feb;304(2):753-760. PMID: 12538831
- Mahajan, KN and **Mitchell, BS**. Role of human Pso4 in mammalian DNA repair and association with terminal deoxynucleotidyl transferase. *Proc Natl Acad Sci USA*, 2003 Sep 16;100(19):10746-10751. PMID: 12960389
- Mitchell, BS**. The proteasome--an emerging therapeutic target in cancer. *N Engl J Med* 2003 Jun 26;348(26):2597-8. PMID: 12826633
- Huang M, Wang Y, **Mitchell BS**, Graves LM. Regulation of equilibrative nucleoside uptake by protein kinase inhibitors. *Nucleosides Nucleotides Nucleic Acids*. 2004 Oct;23(8-9):1445-50. PMID: 15571274
- Spychala J, Lazarowski E, Ostapkowicz A, Ayscue LH, Jin A, **Mitchell BS**. Role of the estrogen receptor in the regulation of ecto-5'-nucleotidase and adenosine in breast cancer. *Clin Cancer Res*. 2004 Jan 15;10(2):708-717. PMID: 14760094
- Aherne A, Kennan A, Kenna PF, McNally N, Lloyd DG, Alberts IL, Kiang AS, Humphries MM, Ayuso C, Engel PC, Gu JJ, **Mitchell BS**, Farrar GJ, Humphries P. On the molecular pathology of neurodegeneration in IMPDH1-based retinitis pigmentosa. *Hum Mol Genet*. 2004 Mar 15;13(6):641-650. PMID: 14981049
- Malek K, Boosalis MS, Waraska K, **Mitchell BS**, and Wright D. Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part I. In vivo studies. *Leuk Res*, 2004 Nove;28(11): 1125-1136. PMID: 15380335
- Gu, JJ, Santiago, L, **Mitchell, BS**. Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl. *Blood* 2005 Apr 15;105(8):3270-3277. PMID: 15604220
- Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T, Johri AR, Jones PE, Ivanova A, Van Deventer HW, Gabriel DA, Shea TC, **Mitchell BS**, Adams J, Esseltine DL, Trehu EG, Green M, Lehman MJ, Natoli S, Collins JM, Lindley CM, Dees EC. Phase I trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. *Blood* 2005 Apr 15;105(8):3085-3065. PMID: 15626743
- Kurtzberg J, Ernst TJ, Keating MJ, Gandhi V, Hodge JP, Kisor DF, Lager JJ, Stephens C, Levin J, Krenitsky T, Elion G, **Mitchell BS**. Phase I study of 506U78 administered

- on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. *J Clin Oncol*. 2005 May 20;23(15):3396-3403. PMID: 15908652
- Hunsucker SA, **Mitchell BS**, Spsychala, J. The 5'-nucleotidases as regulators of nucleotide and drug metabolism. *Pharmacol Ther*. 2005 Jul;107(1):1-30. PMID: 15963349
- Ji YS, Gu JJ, Makhov AM, Griffith JD, and **Mitchell BS**. Regulation of the interaction of inosine monophosphate dehydrogenase with mycophenolic Acid by GTP. *J Biol Chem*, 2006 Jan 6;281(1):206-212. PMID: 16243838
- Douvas MG, Hogan KN, Ji Y, Hollenbeck D, Bonham L, Singer JW, **Mitchell BS**. Effect of lysosphatidic acid acyltransferase-beta inhibition in acute leukemia. *Leuk Res*, 2006 Aug;30(8):1027-36. PMID: 16488473
- DeAngelo DJ, Yu D, Johnson JL, Coutre SE, Stone RM, Stopeck AT, Gockerman JP, **Mitchell BS**, Appelbaum FR, and Larson RA. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. *Blood*, 2007 Jun 15;109(12):5136-5142. PMID: 17344466
- Huang M, Ji Y, Itahana K, Zhang Y, and **Mitchell B**. Guanine nucleotide depletion inhibits pre-ribosomal RNA synthesis and causes nucleolar disruption *Leuk Res*, 2008 Jan;32(1):131-41. PMID: 17462731
- Huang M, Wang Y, Gu J, Yang J, Noel K, **Mitchell BS**, Schramm VL, Graves LM. Determinants of sensitivity of human T-cell leukemia CCRF-CEM cells to immucillin-H. *Leuk Res*, 2008 Aug;32(8):1268-78. PMID: 18279955
- Sadej R, Inai K, Rajfur Z, Ostapkowicz A, Kohler J, Skladanowski AC, **Mitchell BS**, Spsychala J. Tenascin C interacts with ecto-5'-nucleotidase (eN) and regulates adenosine generation in cancer cells. *Biochim Biophys Acta*, 2008 Jan;1782(1):35-40. PMID: 18062933
- Huang M, **Mitchell BS**. Guanine nucleotide depletion mediates translocation of nucleolar proteins, including RNA Helicase A (DHX-9). *Nucleosides Nucleotides Nucleic Acids*, 2008 Jun;27(6):704-11. PMID: 18600529
- Huang M, Itahana K, Zhang Y, **Mitchell BS**. Depletion of guanine nucleotides leads to the Mdm2-dependent proteasomal degradation of nucleostemin, *Cancer Res*, 2009 Apr 1;69(7):3004-12. PMID: 19318567
- Namavari M, Chang Y, Kusler B, Yaghoubi S, **Mitchell BS**, Gambhir S. Synthesis of 2'-Deoxy-2'-[<sup>18</sup>F]fluoro-9-β-D-arabinofuranosylguanine: A Novel Agent for Imaging T Cell Activation with PET. *Mol. Imaging Biology*, 2010. PMID: 20838911
- Huang M, Whang P, Chodaparambil JV, Pollyea DA, Kusler B, Xu L, Felsher DW, **Mitchell BS**. Reactive oxygen species regulate nucleostemin oligomerization and protein degradation. *J. Biol. Chem*. 286:11035-46, 2011 Apr 1;286(13). PMID: 21242306
- Huang, M, Whang, P, Lewicki, P, and Mitchell BS. Cyclopentenyl cytosine induces senescence in breast cancer cells through the nucleolar stress response and activation of p53 *Mol. Pharm.*, 2011 Jul;80(1). PMID: 21464199

Pollyea DA, Raval A, Kusler B, Gotlib JR, Alizadeh AA, Mitchell BS, □  
HYPERLINK "<http://www.ncbi.nlm.nih.gov/pubmed/21922510>" □ Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors. □ Hematol Oncol. 2011 Sep;29(3):157-60. PMID: 21922510

Raval, A, Kusler B, Pang WW, Weissman IL, **Mitchell BS**, Park CY. Effect of haploinsufficiency of nucleophosmin 1 on hematopoietic stem cells. Leukemia 2012 Apr;26(4):853-855. PMID: 21979879

Pollyea DA, Kohrt HE, Gallegos L, Figueroa ME, Abdel-Wahab O, Zhang B, Bhattacharya S, Zehnder J, Liedtke M, Gotlib JR, Coutre S, Berube C, Melnick A, Levine R, **Mitchell BS**, Medeiros BC. Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. Leukemia. 2012 May;26(5):893-901. PMID: 22033493

Patel MI, Ma Y, **Mitchell BS**, Rhoads KF, □ HYPERLINK "<http://www.ncbi.nlm.nih.gov/pubmed/22971999>" Understanding disparities in leukemia: a national study. □ Cancer Causes Control. 2012 Nov;23(11):1831-7. PMID: 22971999

Aparna Raval, Kunju J. Sridhar, Shripa Patel, Brit B Turnbull, Peter L. Greenberg and **Mitchell BS**. Reduced ribosomal RNA expression and increased ribosomal promoter DNA methylation in CD34+ cells from patients with myelodysplastic syndrome. Blood. 2012; 24:4812-8. PMID: 23071274

Pollyea DA, Zehnder J, Coutre S, Gotlib J, Gallegos L, Abdel-Wahab O, Greenberg P, Zhang B, Liedtke M, Berube C, Levine R, **Mitchell BS**, Medeiros BC. □ HYPERLINK "<http://www.ncbi.nlm.nih.gov/pubmed/23242596>" □ Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. □ Haematologica. 2012;98: 591-6. PMID: 23242596

Patel, MI, Ma, Y, **Mitchell BS**, Rhoads, KF. Age and Genetics: How do prognostic factors at diagnosis explain disparities in acute myeloid leukemia? Am. J. Clin. Oncol., 2013. PMID 23608826

Huang M, Thomas D, Li MX, Feng W, Chan SM, Majeti R, **Mitchell BS**. (2013) Role of cysteine 288 in nucleophosmin cytoplasmic mutations: sensitization to toxicity induced by arsenic trioxide and bortezomib. Leukemia. 27(10):1970-80. PMID: 23877794.

Patel M, Ma Y, **Mitchell BS**, Rhoads K. (2013) Age and Genetics: How do prognostic factors at diagnosis explain disparities in Acute Myeloid Leukemia? Am J Clin Onc, PMID: 23608826.

Pollyea DA, Kohrt HE, Gallegos L, Figueroa ME, Abdel-Wahab O, Zhang B, Bhattacharya S, Zehnder J, Liedtke M, Gotlib JR, Coutre S, Berube C, Melnick A, Levine R, **Mitchell BS**, Medeiros BC. (2012) Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. Leukemia. (5):893-901. PMID: 22033493.

Pollyea DA, Zehnder J, Coutre S, Gotlib J, Gallegos L, Abdel-Wahab O, Greenberg P, Zhang B, Liedtke M, Berube C, Levine R, **Mitchell BS**, Medeiros BC. (2013) HYPERLINK "<http://www.ncbi.nlm.nih.gov/pubmed/23242596>" Sequential

azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. *Haematologica*. 98:591-596. PMID: 23242596.

Nguyen, T. and **Mitchell BS**. (2013) AKT activation enhances ribosomal RNA synthesis through casein kinase II and TIF-1A. *Proc. Natl. Acad. Sci. (USA)* 2013 Dec 17;110(51):20681-6. PMID: 24297901.

Huang M, Thomas D, Li MX, Feng W, Chan, SM, Majeti R, **Mitchell BS**. Role of Cysteine 288 in the cytoplasmic localization of NMPc+ and in sensitivity to Bortezomib. *Leukemia*. 2013 Oct;27(10):1970-80. PMID:23877794.

Nguyen, T, Huang, M, Chan, SM, Ngo, TD, Raval, A, Kim, KK, Majeti, R, and **Mitchell BS**. Interaction of TIF-90 and Filamin A in the regulation of rRNA synthesis in leukemic cells. *Blood*, 124:579-89, 2014. PMID: 25014775.

Nguyen, LX, Sesay, A, **Mitchell BS**. Effect of CAL-101, a PI3Kd inhibitor, on ribosomal RNA synthesis and cell proliferation in acute leukemia cells. *Blood Cancer J.* , 2014. PMID: 25014775.

Nguyen, LX, Raval, A, Garcia, JS, **Mitchell BS**. Regulation of ribosomal gene expression in cancer. *J. Cell Physiol.*, 2015. PMID 24850755.

Nguyen, LX, Lee Y, Urbani L, Utz PJ, Hamburger AW, Sunwoo JB, **Mitchell BS**. Regulation of ribosomal RNA synthesis in T Cells: requirement for GTP and Ebp1, *Blood*, 2015. PMID: 25691158.

Huang, M, Garcia, J, Thomas, D, Cai, S, Zhu, L, Chan, S, Majeti, R, Medeiros, B, **Mitchell BS**. Autophagy enhances leukemic cell sensitivity to oxidant stress through Nrf2. Submitted.

Burns LJ, Clayton CP, George JN, **Mitchell BS**, and Gitlin SD. The Effect of an Intense Mentoring Program on Junior Investigators' Preparation for a Patient-Oriented Clinical Research Career. *Academic Medicine*, Vol. xx, No. x/xx xxxx

Garcia JS, Huang M, Medeiros BC, **Mitchell BS**. Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species. *Clin Cancer Res*. 2015 Dec 3; doi:10.1158/1078-0432. CCR-15-1440

Nguyen LX, Zhu L, Lee Y, Ta L, **Mitchell BS**. Expression and Role of the ErbB3 Binding Protein 1 in Acute Myelogenous Leukemic Cells. *Clin Cancer Res*. 2016 Jan 26. pii: clincanres.2282.2015

Min Huang, Jacqueline Garcia, Daniel Thomas, Li Zhu, Le Truong, Steven Chan, Ravindra Majeti, Bruno Medeiros, **Beverly Mitchell**. Autophagy mediates proteolysis of NPM1 and HEXIM1 and sensitivity to BET inhibition in AML cells, *Oncotarget*, in Press. 2016

#### **Non-Peer Reviewed Articles, Reviews and Editorials:**

**Mitchell B**, and Adamson J. Granulocyte and erythroid colony forming cells from rat marrow: Studies of physical and cell cycle characteristics and competition for expression. In *Erythropoiesis*, Nakao, K., Fisher J, Pakaku, F. (Eds) University Park Press, 1975. PMIC:

- Wortmann RL, **Mitchell BS**, Edwards NL, and Fox IH. Possible role for 5'-nucleotidase in deoxyadenosine selective toxicity to cultured human lymphoblasts. *Adv Exp Med Biol* 1979; 122B:243-259. PMID: 232631
- Wilson JM, **Mitchell BS**, and Kelley WN. Molecular mechanism(s) of deoxyribonucleoside toxicity in T-lymphoblasts. *Adv Exp Med Biol* 1979;122B:265-270. PMID: 317565
- Mitchell BS**, Koller CA, and Kelley WN. Treatment of acute lymphoblastic leukemia with the adenosine deaminase inhibitor 2'-deoxycoformycin. *Adv Exp Med Biol* 1979;122B:347-350. PMID: 317568
- Paredes JM, and **Mitchell BS**. Multiple myeloma: current concepts in diagnosis and management. *Med Clin North Am* 1980 Jul;64(4):729-742. PMID: 6995732
- Mitchell BS**. Deficiencies of adenosine deaminase and purine nucleoside phosphorylase: Implications for immunopharmacology. *Med Gr Rounds* 1982; 1:85-93.
- Schnitzer B, Lovett E, Hudson J, McClatchey K, Keren D, Dabich L, and **Mitchell B**. Adult T-cell leukaemia-lymphoma with unusual phenotype. *The Lancet (Letter)*, 1982 December;1273-1274.
- Koller C, and **Mitchell B**. Erythrocyte ATP and dATP measurements predict toxicity following 2'-deoxycoformycin therapy. *Cancer Treat Symp* 1984; 2:67-74.
- Mitchell BS**, Sidi Y, Hershfield M, and Koller CA. Biochemical consequences of adenosine deaminase inhibition in vivo. Differential effects in acute and chronic T cell leukemia. *Ann NY Acad Sci* 1985;451:129-137. PMID: 3878114
- Shewach DS, and **Mitchell BS**. Characterization of arabinosylguanine resistance in a lymphoblastoid cell line. *Adv Exp Med Biol* 1986;195 Pt B:605-609. PMID: 3094330
- Chottiner EG, Ginsburg D, and **Mitchell BS**. Autosomal dominant hemolytic anemia and adenosine deaminase overproduction. *Adv Exp Med Biol* 1989;253A:493-497. PMID: 2624229
- Chottiner EG, Gribbin TE, Ginsburg D, and **Mitchell BS**, Erythrocyte-specific overproduction of adenosine deaminase: molecular genetic studies. *Prog Clin Biol Res* 1989; 319:55-64; discussion 65-68. PMID: 2622927
- Datta NS, Shewach DS, Hurley MC, **Mitchell BS**, and Fox IH. Properties of highly purified human T lymphoblast (MOLT-4) deoxycytidine kinase. *Adv Exp Med Biol* 1989;253B:87-92. PMID: 2558550
- Thompson CB, Jackson KM, Turka LA, **Mitchell BS**, and June CH. "Development of an in vitro model system to study the physiologic effects and toxicities of immunosuppressants." *Vitro Toxicology: Mechanisms and New Technology. Alternative Methods in Toxicology*, Vol. 8. A.M. Goldberg, ed. Mary Ann Liebert, Inc., 1991; 55-61.
- Dayton JS, Turka LA, Thompson CB, and **Mitchell BS**. Guanine ribonucleotide depletion inhibits T cell activation. *Adv Exp Med Biol* 1991;309B:293-6. PMID: 1781385



**Mitchell BS**, Dayton JS, Turka LA and Thompson CB. IMP dehydrogenase inhibitors as immunomodulators. *Ann NY Acad Sci*, 1993 Jun 23;685:217-224. PMID: 8103312

**Mitchell BS**, Song JJ, Johnson EE 2nd, Chen E, Dayton JS. Regulation of human deoxycytidine kinase expression. *Adv Enzyme Regul* 1993;33:61-68. PMID: 8356917

Spychala J and **Mitchell BS**. Regulation of low Km (ecto-) 5'-nucleotidase gene expression in leukemic cells. *Adv Exp Med Biol* 1994;370:683-687. PMID: 7660996

Zimmermann A, Gu JJ, Spychala J, and **Mitchell BS**. Inosine monophosphate dehydrogenase expression: transcriptional regulation of the type I and II genes. *Adv Enzyme Regul* 1996;36:75-84. PMID: 8869741

**Mitchell B**, and Brecher M. A 73-year-old woman with anemia and thrombocytopenia. *J Am Geriatr Soc* 1996 Jun;44(6):723-726. PMID: 8642168

Zimmermann AG, Gu JJ, Laliberté J, **Mitchell BS**. Inosine-5'-monophosphate dehydrogenase: Regulation of expression and role in cellular proliferation and T lymphocyte activation. *Prog Nucleic Acid Res Mol Biol* 1998;61:181-209. PMID: 9752721

### Chapters in Books

**Mitchell, B**, Wilson, J, Mejias, E, and Kelley, W. "Differential effects of deoxyribonucleosides on human T and B lymphoblast cell lines." *Inborn Errors of Specific Immunity*, Pollara, B. et al. (Eds) Academic Press, 1979.

**Mitchell, B** and Kelley, W. "Disorders of purine metabolism that lead to immunodeficiency." *Harrison's Principles of Internal Medicine 10th edition*, Petersdorf R, et al. (Eds) McGraw-Hill, 1983.

**Mitchell, BS**. "Purinogenic immunodeficiency diseases." *Human Inflammatory Disease: Clinical Immunology Vol. I*, 203-210; G Marone et al, (Eds) B.C. Decker, Inc. Toronto, 1988.

Dayton, JS and **Mitchell, BS**. "Mizoribine: Immunosuppressive activity and mechanism of action." *Recent Developments in Transplant Medicine*, 129-137, 1994.

Hershfield, M and **Mitchell, BS**. "Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency." *Metabolic and Molecular Bases of Inherited Disease*, VII,1725-1768, 1995.

**Mitchell, BS** and Hershfield, M. "Disorders of purine and pyrimidine metabolism." *Cecil's Textbook of Medicine*, XV, 1114-1117, 1995.

**Mitchell, BS**. "Principles of Cancer Treatment." *Internal Medicine, Fifth Ed.* Stein et al. Mosby, pp. 550-555, 1998.

**Mitchell, BS** and Hershfield, M. "Disorders of purine and pyrimidine metabolism." *Cecil's Textbook of Medicine*, XVI, 1999.

Hershfield, M and **Mitchell, BS**. "Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency." *Metabolic and Molecular Bases of Inherited Disease*, VIII, 2001.

Hershfield, M and **Mitchell, BS**. “Disorders of purine and pyrimidine metabolism.” Cecil’s Textbook of Medicine, XVII, 2002.

**Mitchell, BS**. “Leukemia.” Netter's Internal Medicine. Runge, M. and Greganti, A., eds. pp. 411-415. Icon Publications; Teterboro, NJ. 2003.

Hunsucker, SA, Spychala, J, **Mitchell, BS**. “Ecto-5’-nucleotidase: structure and function.” Submitted.

Gu JJ, Stegmann S, and **Mitchell BS**. “Targeted disruption of the IMPDH type II gene: Effect on mouse development and lymphocyte activation.” Inosine Monophosphate Dehydrogenase: A major therapeutic target. Pankiewicz, K., and Goldstein, B. eds. Oxford University Press, 2003.

Hunsucker SA, **Mitchell BS**, and Spychala, J. “Nucleotidases and Deoxynucleoside Cytotoxicity.” Deoxynucleoside Analogs in Cancer Therapy (Peters GJ ed) The Humana Press, Inc. Totowa, NJ, 2006.

Kelly H, and **Mitchell BS**. “Leukemia” in Netters Textbook of Internal Medicine. M. Runge and A. Greganti, eds, 2008.

Updated Sept. 1, 2016